ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Sun Pharmaceutical Industries Ltd.

Business Summary

Sun Pharmaceutical Industries Ltd. engages in manufacturing, developing, and marketing of pharmaceuticals products. It operates through the following geographical segments: India, United States of America, Emerging Markets, and Rest of the World. It offers tablets, capsules, injectable, inhalers, ointments, creams, and liquids. The company was founded by Dilip Shantilal Shanghvi in 1982 and is headquartered in Mumbai, India.

Financial Highlights

Mar 2019 INRUSD
Gross Profit122,523.20M1,751.76M
Operating income49,220M703.71M
Income before tax38,102M544.76M
Net income26,654.20M381.08M
Diluted EPS11.100.15
Dividends Per Share2.750.03
Total Assets655,799.50M9,466.61M
Total liabilities208,573.50M3,010.80M
Total equity414,090.60M5,977.48M
Operating cash flow24,425.10M349.21M
Currency in INRCurrency in USD

Historical Data

 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 272,865M 281,086.10M 313,081.40M 264,155.40M 290,659.10M
Gross Profit 140,261.50M 149,951.40M 158,651.20M 109,049.50M 122,523.20M
Operating income 68,831.20M 75,140.60M 84,884.50M 41,097.80M 49,220M
Income before tax 64,029M 65,706.30M 90,478.70M 34,789.80M 38,102M
Net income 45,393.80M 45,457.10M 69,643.70M 20,957M 26,654.20M
EBITDA 80,778.40M 85,515.90M 97,532M 56,096.20M 66,752.50M
Diluted EPS 18.90 18.90 29 8.73 11.10
Dividends Per Share 3 1 3.50 2 2.75
Total Assets 494,235.80M 559,415.90M 619,117.90M 652,045.20M 655,799.50M
Total liabilities 209,343M 188,572.10M 214,674.70M 230,062.50M 208,573.50M
Total equity 256,231.90M 329,824.80M 366,396.70M 383,141.10M 414,090.60M
Operating cash flow 53,591.20M 67,726.30M 71,269.50M 39,781.60M 24,425.10M
 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 4,462.70M 4,293.30M 4,668.88M 4,097.58M 4,155.67M
Gross Profit 2,293.97M 2,290.35M 2,365.91M 1,691.58M 1,751.76M
Operating income 1,125.73M 1,147.69M 1,265.85M 637.51M 703.71M
Income before tax 1,047.19M 1,003.59M 1,349.27M 539.66M 544.76M
Net income 742.41M 694.31M 1,038.57M 325.08M 381.08M
EBITDA 1,321.12M 1,306.16M 1,454.46M 870.16M 954.38M
Diluted EPS 0.30 0.28 0.43 0.13 0.15
Dividends Per Share 0.04 0.01 0.05 0.03 0.03
Total Assets 7,897.50M 8,447.51M 9,534.42M 9,997.36M 9,466.61M
Total liabilities 3,345.13M 2,847.55M 3,305.99M 3,527.39M 3,010.80M
Total equity 4,094.38M 4,980.55M 5,642.51M 5,874.44M 5,977.48M
Operating cash flow 876.48M 1,034.44M 1,062.81M 617.09M 349.21M

Valuation Measures

Mar 2019
Operating margin16.93%
Profit margin9.17%

Key executives

  • Managing Director & Executive Director: Dilip Shantilal Shanghvi
  • Chief Financial Officer: C. S. Muralidharan
  • SVP & Chief Information Officer: Atanu Roy
  • Compliance Officer & Senior GM-Secretarial: Ashok I. Bhuta
  • SVP & Head-Human Resources: Sapna Purohit


  • Life Insurance Corp. of India (5.8%)
  • ICICI Prudential Asset Management Co. Ltd. (3.6%)
  • Aditya Medisales Ltd. (1.6%)
  • Reliance Nippon Life Asset Management Ltd. (Invt Mgmt) (1.6%)
  • The Vanguard Group, Inc. (1.6%)
  • Lakshdeep Investments & Finance Pvt Ltd. (1.3%)
  • GIC Pte Ltd. (Investment Management) (1.2%)

Contact Details

  • Website:
  • Address: CTS No. 201 B/1, Sun House, Western Express Highway, Mumbai, 400063, India
  • Phone: +91.22.43244324

Related Companies

  • Sun Pharmaceuticals Germany GmbH
  • Sun Pharmaceuticals Morocco LLC Sarlau
  • Sun Pharma Netherlands BV
  • Sun Pharmaceutical Industries (Australia) Pty Ltd.
  • Ocular Technologies SARL
  • Sun Pharmaceutical Industries Ltd. /7 Brands/
  • Sun Pharmaceutical Industries Ltd. /Bryan Ops/
  • Sun Pharma Japan Ltd.
  • GlaxoSmithKline Plc /Opiates Business/
  • Sun Pharma Laboratories Ltd.
  • Sun Global Canada Pty Ltd.
  • Sun Pharmaceutical Industries Europe BV
  • Aditya Acquisition Co. Ltd.
  • SPIL de Mexico SA de CV
  • Sun Pharma de Mexico SA de CV
  • Tamil Nadu Dadha Pharmaceuticals Ltd.
  • Pradeep Drug Co. Ltd.
  • Pola Pharma, Inc.
  • Ranbaxy
  • Pharmalucence, Inc.
  • Alkaloida Chemical Co. Exclusive Group Ltd.
  • Sun Pharmaceutical Industries Key Employees Benefit Trust
  • Sun Pharmaceutical Industries, Inc.
  • Chattem Chemicals, Inc.
  • Generic Pharmaceutical Co.
  • Zenotech Laboratories Limited
  • MJ Pharmaceuticals Ltd. /Manufacturing Business/
  • MJ Pharmaceuticals Pvt Ltd.
  • Phlox Pharmaceuticals Ltd.
  • Hindustan Antibiotics Ltd.


  • Dr. Reddy's Laboratories Ltd.
  • Cipla Limited
  • Glenmark Pharmaceuticals Limited
  • IPCA Laboratories Limited
  • Wockhardt Limited
  • FDC Ltd.
  • Lupin Limited
  • Torrent Pharmaceuticals Ltd
  • Cadila Healthcare Limited
  • Amneal Pharmaceuticals, Inc. Class A
  • ANI Pharmaceuticals, Inc.
  • Zentiva SA
  • Plus Therapeutics, Inc.
  • Antares Pharma, Inc.
  • Aerie Pharmaceuticals, Inc.
  • Nicox SA
  • Cumberland Pharmaceuticals Inc.
  • Piramal Enterprises Ltd.
  • Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A
  • Curis, Inc.
  • Acura Pharmaceuticals, Inc.
  • BioPharmX Corp.
  • Evolus, Inc.
  • Intec Pharma Ltd
  • Sol-Gel Technologies Ltd.
Last Updated on 19 Sep, 2019

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends June 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media